News

Prestigious grant recognising APPA’s game-changing potential



AKL Research & Development's pioneering approach to tackling OA has secured a prestigious grant of £675,000 ($900,000) from Innovate UK, which is part of the Government’s UK Research and Innovation (UKRI) organisation, to contribute to the development of APPA in its Phase 2 trial. This is expected to begin later this year following anticipated favourable results of the Phase 1 trial currently underway at the University of Liverpool, which ...
Read More

Dr Annalisa Jenkins and Lord Michael Grade as Advisors



AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, announces the appointment of Dr Annalisa Jenkins and Lord Michael Grade as advisors. Dr Jenkins is former Head of Global Research & Development and Executive Vice President Global Development & Medical at Merck Serono. Lord Grade is former Chairman of the BBC. Current Chief Operating Officer (COO) of AKLRD David Miles has bee...
Read More

More weight loss tied to less knee pain for obese people



A recent article from Reuters Health has highlighted research by the American College of Rheumatology whose researchers have determined that obese people with knee osteoarthritis, a painful joint disease, may find greater symptom relief when they lose larger amounts of weight than when they shed fewer pounds, a recent study suggests. The researchers examined data on 240 obese adults with pain from knee osteoarthritis who were participating in an...
Read More

Phase I Clinical Trial at the University of Liverpool



The Phase I Clinical Trial to test AKL’s lead anti-inflammatory clinical candidate, APPA, as a potential new treatment for osteoarthritis is underway at the University of Liverpool Clinical Trials Unit. The trial has been approved for NIHR support. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people, and is the leading cause of joint pain and stiffness in older people. Improved func...
Read More

MHRA Approval for Formal Human Trials to Start



The University of Liverpool, as Sponsor of APPA's clinical program, has received clinical trial authorisation (CTA) from the MHRA (Medicines & Healthcare Products Regulatory Agency) to commence the Phase I clinical trial. The ongoing clinical program will test AKLRD’s lead candidate, APPA, as a potential new treatment for osteoarthritis. David Sharples, Chief Executive Officer at ALKRD Ltd, said "This is a huge achievement for AKLRD and ...
Read More

Under-exploited plants offer untold economic promise



A recent article in Nature by Ameenah Gurib Fakim, President of Mauritius and former Professor of Organic Chemistry, about the abundance of commercially available drugs that have their origins in plants. "Artemisinin, ginkgolides, quinine, reserpine, scopolamine, paclitaxel. What do these molecules have in common? They are all extracted from plants and transformed into useful drugs, treating conditions including malaria, nausea, cancer and hig...
Read More

AKLRD and APPA in the Press



Recently there have been various press reports on AKLRD's collaboration with Liverpool University on the clinical development of APPA. There has been coverage in both industry and mainstream press with Prof Rob Moots and Prof Steven Edwards being quoted extensively.     Pharma Times: Liverpool Uni leads clinical trial of promising osteoarthritis drug Drug Development Technology: Liverpool and AKLRD collaborate to evaluate APPA...
Read More

Liverpool University Press Release



Clinical trial for new innovative Osteoarthritis drug The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people*, and is the leading cause of joint pain and stiffness in older people. As part of their research and dev...
Read More